Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q3 FY22 results · Oct–Dec 2021
Sun Pharma Advanced Research Company reported revenue from operations of ₹62.15 crore (up 185.0% from Q3 FY21) and net loss of ₹15.84 crore for Q3 FY22 (Oct–Dec 2021), on a standalone basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 62.15 | 21.81 | +185.0% | 27.87 | +123.0% |
| Other income | 0.34 | 1.60 | −78.8% | 5.98 | −94.3% |
| Total income | 62.49 | 23.41 | +166.9% | 33.85 | +84.6% |
| Profit before tax | (15.84) | (67.62) | Loss narrowed | (55.14) | Loss narrowed |
| Net profit for the period | (15.84) | (67.62) | Loss narrowed | (55.14) | Loss narrowed |
| EPS, basic (₹) | (0.60) | (2.58) | Loss narrowed | (2.09) | Loss narrowed |
| Net margin (%) | -25.5 | -310.0 | -197.8 |
Standalone
- Filed with BSE
- 05 Feb 2022, 09:06 IST
- Board meeting
- 04 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE